Social Media Content Creators Driving Unofficial Trade for Unlicensed Slimming Medication
A shadow market for unapproved weight-loss drugs is being driven by TikTok fitness influencers and vendors on messaging platforms, according to new investigations.
Experimental Treatment Acquiring Traction Via Social Media
The experimental drug, which is still in clinical trials, is being advertised by social media influencers for its supposed weight-reducing properties. Followers are encouraged to contact these profiles directly for supplier links, while also obtaining discount codes.
Thriving Commerce on Messaging Platforms
Additionally, a flourishing trade exists on Telegram, where communities with thousands of members share “before and after” photos, administration instructions and claims of next-day UK delivery. Sellers promote the substance there before redirecting buyers to WhatsApp for purchases.
Understanding The Experimental Drug
Retatrutide is an investigational injectable created by US drugmaker Eli Lilly. The treatment affects three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon. Early trials suggest it could help patients reduce up to a quarter of their body weight. Referred to as the “triple G”, the drug is being promoted online as the next Ozempic.
Medical Professionals Express Worries
However, doctors and chemists have cautions that the distribution of what remains an unlicensed drug in the United Kingdom is worrisome and could result in individuals administering substances of unknown origin.
Some professionals said the popularity for the experimental drug could be connected to the rising cost of licensed weight loss products such as Mounjaro.
Legal Status and Enforcement
Marketing retatrutide on TikTok or Telegram is prohibited in the United Kingdom, as it is an unlicensed drug that cannot be marketed or distributed for personal consumption under the Human Medicines Regulations 2012.
Some content creators attempt to circumvent the rules by referring to the substance as a “research chemical” or describing it as “not for human consumption”. The substance is not a restricted drug, but promotion and supply can still violate medicines, marketing, and consumer laws, potentially leading to fines, legal action or prison.
Platform Reaction and Content Removal
Based on the social media company, the platform has removed problematic material and prohibited related hashtags and query recommendations. The company stated it was dedicated to maintaining the service safe and investing in strengthening enforcement strategies.
Online Trading Activities
Investigations also found groups with up to 9,000 members selling retatrutide using the platform's integrated discovery tool, which operates like a online catalog. Typing “retatrutide” instantly brings up groups with thousands of members, populated with images of weight loss, glowing testimonials and step-by-step guides for mixing or administering at home.
After moments of entering one group, a seller shared contact information, where the majority of purchases occur. The seller sent an guidebook and guaranteed delivery within 48 hours. When questioned whether the substance was genuine, one seller said: “You can’t be sure.” Another provided a photo of a supposed laboratory certificate. Not one inquired about weight, health issues or past usage.
Item Information and Pricing
Inside these groups, messages display black plastic packages with Royal Mail stickers, claiming to include new batches. One communication stated: “It took eight of us to load them this morning.”
Customers can select between powder vials, prepared at home with purified liquid, or pre-filled injectors usually sold at £160 for 20 milligrams. When questioned how much time a injector should be used, vendors give conflicting responses varying between a few weeks to “depends on your body”.
Service Oversight and Security Actions
A representative for Telegram stated it regularly monitored dangerous material on its platform including material that promoted the “misuse of controlled medications”. The company noted that it removed “millions of pieces of harmful content each day”.
Healthcare Professional Cautions
“People are injecting substances they cannot confirm. Although the research behind retatrutide is sound, these online versions may not include what they advertise,” said Jason Murphy, the director of pharmacy at a pharmacy service.
Dr Crystal Wyllie of Asda Online Doctor connected the increase in interest to current cost increases for approved weight-loss drugs such as Mounjaro. “With costs rising, individuals are turning to online platforms. But counterfeit injections are extremely risky. You can’t be certain what’s contained or whether the environment they were produced in was sterile,” she explained.
Her staff has already seen patients injured by self-injection from unverified sources. “We understand the frustration, but purchasing from messaging apps or communication platforms is gambling with your well-being,” said Wyllie. “These materials could be impure or incorrectly dosed.”
Producer Statement
A spokesperson from the pharmaceutical company said the substance was in phase 3 clinical trials and had not been reviewed or approved by any regulatory agency anywhere in the world. “Therefore at this point no one can market [it] for personal consumption,” they said, adding that any product “misleadingly claiming itself as a company experimental substance not yet approved … may subject patients to possibly serious health risks”.
